Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (431-440 of 505) with videos related to

Pageof 51
Sort By:
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
The European Respiratory Journal|March 28, 2025
A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4Dave Singh, Patricia Guller, Fred Reid, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
The European Respiratory Journal|March 26, 2021
Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and <i>Haemophilus</i> infection in COPDSofia Winslow, Lina Odqvist, Sarah Diver, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trialsLui G Franciosi, Zuzana Diamant, Katharine H Banner, et al.
Pulmonary Pharmacology & Therapeutics|February 25, 2023
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta SyndromeMalcolm Begg, Augustin Amour, Emily Jarvis, et al.
Respiratory Research|June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialNicola C Day, Subramanya Kumar, Gerard Criner, et al.
Pragmatic and Observational Research|January 26, 2024
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICSDavid Price, William Henley, José Eduardo Delfini Cançado, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Chest|October 8, 2020
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment TrialNicola A Hanania, David M Mannino, Gerard J Criner, et al.
Pageof 51

Showing results (431-440 of 505) with videos related to

Sort By:
Pageof 51
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
The European Respiratory Journal|March 28, 2025
A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4Dave Singh, Patricia Guller, Fred Reid, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
The European Respiratory Journal|March 26, 2021
Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and <i>Haemophilus</i> infection in COPDSofia Winslow, Lina Odqvist, Sarah Diver, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trialsLui G Franciosi, Zuzana Diamant, Katharine H Banner, et al.
Pulmonary Pharmacology & Therapeutics|February 25, 2023
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta SyndromeMalcolm Begg, Augustin Amour, Emily Jarvis, et al.
Respiratory Research|June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialNicola C Day, Subramanya Kumar, Gerard Criner, et al.
Pragmatic and Observational Research|January 26, 2024
Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICSDavid Price, William Henley, José Eduardo Delfini Cançado, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Chest|October 8, 2020
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment TrialNicola A Hanania, David M Mannino, Gerard J Criner, et al.
Pageof 51